Trial Profile
Dose tapering and Early Discontinuation to InCreAse cosT-effectIveness Of immunotherapy for Non-small cell lung carcinoma trial number 1
Status:
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 13 Jul 2023
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Mesothelioma; Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms Dedication-1
- 15 Aug 2020 Planned number of patients changed from 117 to 750.
- 15 Aug 2020 Protocol amended to change study drug from Pemetrexed to pembrolizumab. Planned number of patients, primary end point were changes as reported by European Clinical Trials Database record.
- 06 Sep 2018 New trial record